Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Chad Robins
AddedMar 31, 2024
UpdatedMay 31, 2026
Chad Robins

Chad Robins

CEO, Adaptive Biotechnologies

CrunchbaseLinkedIn

Chad Robins's Career

Adaptive Biotechnologies
Adaptive Biotechnologies

Seattle, WA, US

CEO· C-Suite · Management
Aortica
Aortica

Mercer Island, WA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Chad Robins's Career

Adaptive Biotechnologies
Adaptive Biotechnologies
Public$531.9M7902009Seattle, WA, US
CEO· C-Suite · Management

Leadership at Adaptive Biotechnologies

Peter NeupertPeter NeupertBoard Member
Edus WarrenEdus WarrenBoard Member
Craig WeissmanCraig WeissmanBoard Member
Robert HershbergRobert HershbergBoard Member
Christopher CarlsonChristopher CarlsonCo-Founder
Katey Einterz OwenKatey Einterz OwenBoard Member

Similar to Adaptive Biotechnologies

SeagenSeagenBothell, WA, USCancer Treatmentsest. 1997SeagenBothell, WA, US · est. 1997

Global biotech innovator developing cancer treatments.

Public · $1.7B3.3k
HI-BioHI-BioSan Francisco, CA, USBiotechest. 2021HI-BioSan Francisco, CA, US · est. 2021

HI-Bio pioneers precision medicine, targeting cellular drivers to treat immune-mediated diseases.

Series B · $215M48
Mission BioMission BioSouth San Francisco, CA, USMedical Devicesest. 2014Mission BioSouth San Francisco, CA, US · est. 2014

Mission Bio, a California-based medical organization, offers the unique Tapestri Platform for precise disease detection and treatment response in oncology.

Series D · $150.9M122
FluidigmFluidigmSouth San Francisco, CA, USBiotechnologyest. 1999FluidigmSouth San Francisco, CA, US · est. 1999

Standard BioTools Inc., based in South San Francisco, accelerates life sciences research with essential, standardized technologies.

Public615
Aortica
Aortica
Acquired$8M02014Mercer Island, WA, US
Board Member· Board

Leadership at Aortica

Benjamin StarnesBenjamin StarnesCo-Founder

Chad Robins's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Chad Robins

Harlan RobinsHarlan RobinsCo-Founder · Adaptive BiotechnologiesLance PerkinsLance PerkinsCEO · Adaptive TechnologiesGerald NepomGerald NepomBoard Member · Adaptive BiotechnologiesRonak MassandRonak MassandCo-Founder · Adaptive